The Appen Limited (ASX: APX) share price was up as much as 3.5% today and was only a few cents away from an all-time high. Is it too late to buy?
Appen provides data for machine learning and artificial intelligence. Basically, it provides and improves data for the development of artificial intelligence and machine learning products. With more than 20 years of experience in over 130 countries, Appen has firmly established itself as a global leader in this space.
APX Share Price Higher, No News
The Appen share price has continued moving higher today despite no specific news from the company since their annual report late last month. Since the beginning of March, shares have traded in a very narrow range, but the move today puts the share price just a few cents away from the all-time high closing price of $26.03.
While the company looks overvalued by traditional metrics, it has continued to surprise many investors and keeps pushing higher with the likes of Afterpay Touch Group Ltd (ASX: APT) and Altium Ltd (ASX: ALU).
Is It Too Late To Buy Appen?
While I would say Appen looks expensive, that hasn’t stopped the share price moving higher over the last 12 months.
The most recent annual report shows revenue growth of 119% and EBITDA growth of 206%, suggesting that the current price may be justified by the astronomical growth rate. If Appen continues to grow at this kind of pace, it could be a very profitable long-term investment.
The share price is also fairly volatile, so a patient investor may get an opportunity to buy at a more reasonable price. Whatever your strategy, Appen is certainly a company worth looking at.
For other growth share ideas, check out the companies in the free report below.
After searching through a market with over 2,000 shares, our lead expert investment analyst has narrowed it down to just 2 of his favourite rapid-growth shares in a FREE report to Rask Media readers.
Over the past five years, these two shares have gone from being 'tiny caps' to being serious contenders for the ASX 200.
Idea #1 is taking on the world, starting with the huge USA market. In a just a few short years the company has snatched market share away from rivals and is on its way to being the market leader.
Idea #2 uses a 'printer and cartridge' type model to get large and established customers: a) using their healthcare industry-leading product, b) paying for it again and again and again... so it's little wonder this company is tipped to grow at a rapid pace in 2019.
Access the free report by clicking here now. Absolutely no credit card or payment details required.
Disclaimer: Any information contained in this article is limited to general financial/investment advice only. The information has not taken into account your specific needs, goals or objectives, so please consider consulting a licenced and trusted adviser before acting on the information. Please read The Rask Group’s Financial Services Guide (FSG) for more information. This article is authorised by Owen Raszkiewicz of The Rask Group, which is a corporate authorised representative No. 1264179 of Strawman Pty Ltd (ACN: 610 908 211) (AFSL: 501 223).
Disclosure: At the time of writing, Max does not own shares in any of the companies mentioned.